A phase II trial of GW786034 (pazopanib) in patients with recurrent glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 25 Jan 2017 Trial focus has been changed from TU to TU and AR.
- 04 May 2012 Actual end date changed from 1 Dec 2008 to 1 Mar 2009 as reported by ClinicalTrials.gov.
- 12 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.